Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases (NCT02993146)
Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
🩺 Plain-English Summary (8th-Grade Level)
This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases). Ropidoxuridine may help whole brain radiation therapy work better by making cancer cells more sensitive to the radiation therapy.
Who can join: Review the eligibility criteria below.
Location: UC San Diego Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- UC San Diego Moores Cancer Center — La Jolla, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Wayne State University/Karmanos Cancer Institute — Detroit, Michigan
- Weisberg Cancer Treatment Center — Farmington Hills, Michigan
- University of Nebraska Medical Center — Omaha, Nebraska
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- Ben Taub General Hospital — Houston, Texas
- Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematopoietic and Lymphoid Cell Neoplasm
- An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study — Jonesboro, Arkansas
- Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians — Houston, Texas
- Parental Attitudes and Beliefs Regarding Risks Associated With Opioid Use in Children With Cancer — Houston, Texas
- A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation — Duarte, California
- A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy — Duarte, California
- Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant — Houston, Texas
Explore by condition: All Hematopoietic and Lymphoid Cell Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.